OpenPrescribing Hospitals, an Open Access Analytics Platform for Hospital Medicines Use in England: Development and Implementation Study
Development and implementation of an open access analytics platform for hospital medicines use in England.
This is a beta version of OpenPrescribing Hospitals for testing and feedback purposes. Data and functionality may be incomplete. Please contact us if you find any issues or have feedback. Sign up for email alerts to stay updated.
Development and implementation of an open access analytics platform for hospital medicines use in England.
A publicly available measure on the OpenPrescribing Hospitals platform for best value direct oral anticoagulants (DOACs) issued in the NHS in England in secondary care.
A descriptive observational study of CDK4/6 inhibitor (palbociclib, ribociclib, and abemaciclib) uptake and dose reduction in NHS trusts in England, using OpenPrescribing Hospitals
Development and implementation of an open access analytics platform for hospital medicines use in England.
A publicly available measure on the OpenPrescribing Hospitals platform for best value direct oral anticoagulants (DOACs) issued in the NHS in England in secondary care.
An analysis of national prescribing data in England to assess the impact of the pancreatic enzyme replacement therapy (PERT) shortage, beginning in June 2023, on prescribing, with validation using OpenPrescribing and OpenPrescribing Hospitals.
This study explored trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS Trusts in England.
Hospitals Data BMJ Paper.
A descriptive observational study of CDK4/6 inhibitor (palbociclib, ribociclib, and abemaciclib) uptake and dose reduction in NHS trusts in England, using OpenPrescribing Hospitals
An analysis of primary and secondary care prescribing data in England to explore trends in the use of lithium in England between 2015-2024.